Azithromycin API for Pediatric Oral Suspension Formulations
Azithromycin oral suspension is one of the most widely prescribed pediatric antibiotic formulations globally, commonly used for conditions like acute otitis media, streptococcal pharyngitis, and community-acquired pneumonia in children. But formulating a pediatric suspension isn’t the same as sourcing API for a standard adult tablet — particle size, taste, and reconstitution stability all become formulation-critical in a way they simply aren’t for solid oral dosage forms.
This guide covers what formulators should know about sourcing Azithromycin API for pediatric suspension formulations specifically, from grade selection to the practical specifications that affect a finished product children will actually take reliably.
Why Pediatric Suspensions Demand a Different Sourcing Approach
A pediatric oral suspension has to solve problems a tablet doesn’t: the API must disperse uniformly in liquid, remain stable once reconstituted, and — critically — be formulated in a way that doesn’t taste unpleasant enough to compromise dosing compliance in young patients. Azithromycin’s inherently bitter taste makes this last point a genuine formulation challenge, and it starts with API-level decisions before taste-masking technology even comes into play.
Azithromycin Dihydrate: The Preferred Form for Suspensions
While Azithromycin is available in multiple forms, the dihydrate form is generally preferred for oral suspension formulations due to its solubility and dispersion characteristics in aqueous vehicles. Confirming which form your supplier is providing and that it’s consistent from batch to batch matters more for suspensions than for solid dosage forms, where minor solubility variances are less likely to affect the finished product’s performance.
Key API Specifications for Suspension Formulators
Particle Size Distribution
Particle size directly affects suspension uniformity, mouthfeel, and how evenly the API disperses when the pharmacist or caregiver reconstitutes the product. Inconsistent particle size can lead to uneven dosing across a bottle’s shelf life as the suspension settles differently between shakes — a real concern for a product where accurate pediatric dosing matters.
Taste and Bitterness Profile
Azithromycin’s inherent bitterness is one of the best-documented formulation challenges in pediatric antibiotics. While taste-masking is primarily addressed through excipients, coatings, and flavoring systems at the formulation stage, API purity and crystal form consistency still play a role in how effectively those taste-masking systems perform batch to batch.
Moisture Content and Stability
Reconstituted azithromycin suspensions typically carry a limited stability window once mixed with water commonly a matter of days rather than weeks — making the starting API’s moisture content and stability profile relevant to how reliably the finished product holds its specification through that use window.
Micronization Consistency
For suspension formulations specifically, buyers should confirm whether the API is supplied pre-micronized to a suspension-appropriate particle size, or whether that processing needs to happen during formulation. This affects both your process planning and your equipment requirements downstream.
Documentation to Request From Your Supplier
- Batch-specific Certificate of Analysis, including particle size distribution data where relevant to your formulation.
- Polymorphic form confirmation (dihydrate vs other forms), consistent across batches.
- Moisture content and residual solvent data, particularly relevant given the aqueous reconstitution environment this API will ultimately be exposed to.
- Stability data supporting your target reconstituted shelf-life claim.
Azithromycin API at Chemox Pharma
Chemox Pharma manufactures Azithromycin API at our WHO-GMP certified facility in Dahej, Gujarat, with documentation support to help formulators confirm the specifications relevant to their intended dosage form including suspension-specific buyers who need particle size and polymorphic form data as part of their formulation development.
Questions to Ask Before You Order
- Which polymorphic form (dihydrate or otherwise) are you supplying, and is it consistent across batches?
- Can you provide particle size distribution data relevant to suspension formulation?
- What moisture content and stability data can you share for aqueous-exposure applications?
- Is the material pre-micronized, or will that processing happen on my end?
Request a Quote for Azithromycin API
If you’re formulating and need an azithromycin api for pediatric suspension which is backed by real specification data, get in touch with Chemox Pharma for a quote and sample evaluation.
FAQs
Q: Why is Azithromycin Dihydrate preferred for oral suspension formulations? Its solubility and dispersion characteristics in aqueous vehicles make it generally better suited to suspension formulations than other available forms.
Q: How long does a reconstituted Azithromycin suspension typically remain stable? Reconstituted azithromycin suspensions generally carry a limited stability window, commonly measured in days rather than weeks — always confirm shelf-life expectations against your specific formulation’s stability data.
Q: Why does particle size matter more for suspensions than for tablets? Particle size affects how uniformly the API disperses in liquid and how consistently it resuspends after settling, which directly impacts dosing accuracy for a liquid pediatric formulation.
Q: Does Chemox Pharma provide particle size and polymorphic form data for Azithromycin API? Yes. Chemox Pharma can provide batch-specific documentation, including particle size and polymorphic form data, to support suspension-specific formulation development.
